Chronic rhinosinusitis in eosinophilic granulomatosis with polyangiitis: clinical presentation and antineutrophil cytoplasmic antibodies.


Journal

International forum of allergy & rhinology
ISSN: 2042-6984
Titre abrégé: Int Forum Allergy Rhinol
Pays: United States
ID NLM: 101550261

Informations de publication

Date de publication:
02 2020
Historique:
received: 13 05 2019
revised: 18 10 2019
accepted: 08 11 2019
pubmed: 4 12 2019
medline: 7 2 2021
entrez: 4 12 2019
Statut: ppublish

Résumé

In this study we aim to describe presenting characteristics and identify prognostic factors for disease resolution in patients with chronic rhinosinusitis (CRS) in the setting of eosinophilic granulomatosis with polyangiitis (EGPA). Patients evaluated at a tertiary care center with diagnoses of EGPA and CRS were identified. Descriptive statistics were obtained. Univariate analysis was used to search for prognostic factors associated with higher Lund-Mackay score at presentation and disease resolution. Forty-four patients were included with a mean age of 52.7 (standard deviation, 14) years. Twenty-one patients (47.7%) were female, all had a diagnosis of asthma, and 36 (83.7%) had eosinophils >10%. Common presenting symptoms for CRS included nasal discharge (87.9%) followed by nasal congestion (83.9%) and facial pain and pressure (83.8%). Medical management of CRS included systemic corticosteroids (93.2%) and systemic antibiotics (75%). Surgical intervention occurred in 29 patients (67%). Nine patients (20.5%) had resolution of sinus symptoms, including 4 with imaging confirmation. Fourteen patients (31.8%) had continued CRS, but with improved symptoms, whereas 9 patients (20.5%) had continued CRS with no improvement in symptoms. Eleven patients (25%) were lost to follow-up and 4 (9.1%) died. Univariate analysis did not show antineutrophil cytoplasmic antibody positivity, presence of peripheral eosinophilia, gender, age, or absence of systemic therapy to be predictive of higher Lund-Mackay score at presentation or predictive of disease resolution. CRS in patients with EGPA is often refractory to medical and surgical management. Treatment of these patients should occur in a multidisciplinary setting.

Sections du résumé

BACKGROUND
In this study we aim to describe presenting characteristics and identify prognostic factors for disease resolution in patients with chronic rhinosinusitis (CRS) in the setting of eosinophilic granulomatosis with polyangiitis (EGPA).
METHODS
Patients evaluated at a tertiary care center with diagnoses of EGPA and CRS were identified. Descriptive statistics were obtained. Univariate analysis was used to search for prognostic factors associated with higher Lund-Mackay score at presentation and disease resolution.
RESULTS
Forty-four patients were included with a mean age of 52.7 (standard deviation, 14) years. Twenty-one patients (47.7%) were female, all had a diagnosis of asthma, and 36 (83.7%) had eosinophils >10%. Common presenting symptoms for CRS included nasal discharge (87.9%) followed by nasal congestion (83.9%) and facial pain and pressure (83.8%). Medical management of CRS included systemic corticosteroids (93.2%) and systemic antibiotics (75%). Surgical intervention occurred in 29 patients (67%). Nine patients (20.5%) had resolution of sinus symptoms, including 4 with imaging confirmation. Fourteen patients (31.8%) had continued CRS, but with improved symptoms, whereas 9 patients (20.5%) had continued CRS with no improvement in symptoms. Eleven patients (25%) were lost to follow-up and 4 (9.1%) died. Univariate analysis did not show antineutrophil cytoplasmic antibody positivity, presence of peripheral eosinophilia, gender, age, or absence of systemic therapy to be predictive of higher Lund-Mackay score at presentation or predictive of disease resolution.
CONCLUSION
CRS in patients with EGPA is often refractory to medical and surgical management. Treatment of these patients should occur in a multidisciplinary setting.

Identifiants

pubmed: 31793227
doi: 10.1002/alr.22503
doi:

Substances chimiques

Adrenal Cortex Hormones 0
Anti-Bacterial Agents 0
Antibodies, Antineutrophil Cytoplasmic 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

217-222

Informations de copyright

© 2019 ARS-AAOA, LLC.

Références

Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol. 1951;27:277.
Vaglio A, Buzio C, Zwerina J. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): state of the art. Allergy. 2013;68:261-273.
Mouthon L, Dunogue B, Guillevin L. Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg-Strauss syndrome). J Autoimmun. 2014;48:99-103.
Moosig F, Bremer JP, Hellmich B, et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis. 2013;72:1011-1017.
Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 2005;52:2926-2935.
Comarmond C, Pagnoux C, Khellaf M, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 2013;65:270-281.
Bacciu A, Bacciu S, Mercante G, et al. Ear, nose and throat manifestations of Churg-Strauss syndrome. Acta Otolaryngol. 2006;126:503-509.
Seccia V, Baldini C, Latorre M, et al. Focus on the involvement of the nose and paranasal sinuses in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome): nasal cytology reveals infiltration of eosinophils as a very common feature. Int Arch Allergy Immunol. 2018;175:61-69.
Nakamaru Y, Takagi D, Suzuki M, et al. Otologic and rhinologic manifestations of eosinophilic granulomatosis with polyangiitis. Audiol Neurotol. 2016;21:45-53.
Petersen H, Goetz P, Both M, et al. Manifestation of eosinophilic granulomatosis with polyangiitis in head and neck. Rhinology. 2015;53:277-285.
Tami TA. Granulomatous diseases and chronic rhinosinusitis. Otolaryngol Clin North Am. 2005;38:1267-1278.
Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med. 2003;115:284-290.
Berti A, Volcheck GW, Cornec D, Smyth RJ, Specks U, Keogh KA. Severe/uncontrolled asthma and overall survival in atopic patients with eosinophilic granulomatosis with polyangiitis. Respir Med. 2018;142:66-72.
Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg. 2015;152(suppl):S1-S39.
Lund VJ, Mackay IS. Staging in rhinosinusitis. Rhinology. 1993;31:183.
Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med. 2015;26:545-553.
Dautremont JF, Rudmik L. When are we operating for chronic rhinosinusitis? A systematic review of maximal medical therapy protocols prior to endoscopic sinus surgery. Int Forum Allergy Rhinol. 2015;5:1095-1103.

Auteurs

Christopher M Low (CM)

Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Rochester, MN.

Karina A Keogh (KA)

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN.

Elias S Saba (ES)

Mayo Clinic Alix School of Medicine, Mayo Clinic, Rochester, MN.

Nelson R Gruszczynski (NR)

Mayo Clinic Alix School of Medicine, Mayo Clinic, Rochester, MN.

Alvise Berti (A)

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN.
Department of Rheumatology, Santa Chiara Hospital, Trento, Italy.
Centre for Integrative Biology, University of Trento, Trento, Italy.

Ulrich Specks (U)

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN.

Misbah Baqir (M)

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN.

Byron M Smith (BM)

Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN.

Garret Choby (G)

Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Rochester, MN.

Janalee K Stokken (JK)

Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Rochester, MN.

Erin K O'Brien (EK)

Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Rochester, MN.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH